Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema
Author(s) -
Arshad M. Khanani,
Sunil Patel,
Víctor H. González,
Suk J. Moon,
Glenn J. Jaffe,
John A. Wells,
Petra Kozma,
Pravin U. Dugel,
Raj K. Maturi
Publication year - 2021
Publication title -
ophthalmology science
Language(s) - English
Resource type - Journals
ISSN - 2666-9145
DOI - 10.1016/j.xops.2021.100040
Subject(s) - medicine , adverse effect , incidence (geometry) , edema , diabetic macular edema , visual acuity , fluorescein angiography , ophthalmology , surgery , diabetes mellitus , diabetic retinopathy , endocrinology , optics , physics
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom